Symposium participants received a comprehensive review of cellular medicine, review current techniques, and learn various applications and protocols for delivering stem cell treatments to patients that address a range of health and aesthetic indications. The field of regenerative medicine is expanding at an exponential rate. The number of clinical trials employing adult stem cells is now in the thousands.
EVENT / what it’s all about
SPEAKERS / meet the experts
AGENDA / event schedule
CEO, Global Stem Cell Group
08:00 - 09:00
Dr Kristen Comella
09:00 - 10:00
Regenerative Medicine for Degenerative Diseases:
The field of regenerative medicine is rapidly growing with an emphasis on stem cell therapies and the promise of cures for everything from acute injuries to chronic degenerative diseases. The list of indications is expanding as more studies are published to demonstrate safety and efficacy.
Regenerative medicine is the process of replacing or regenerating human cells, tissues or organs to restore or establish normal function. The concept is that damaged tissue can be restored by using the body’s own healing mechanism to promote repair. This new branch of medicine may change the course of chronic diseases and standard clinical therapies.
However, with any new therapies, this must be approached cautiously and with scientific data to support the treatment. This session will discuss the use of stem cell therapies in degenerative diseases and the challenges of bringing these products to market.
Dr David Harrell
10:00 - 11:00
Cellular Composition of Bone Marrow with a Focus on Stem and Progenitor Cells!
Activities of Bone Marrow Stem and Progenitor Cells!
Importance of Cellular Mobilization!
Course of Traumatized Tissue!
Importance of Neovascularization!
Cells Crucial for Tissue Regeneration!
Importance of Paracrine Effect and the Microenvironment! Relate Basic Science to Clinical Practice.
Dr Todd Malan
11:00 - 12:00
The Practical Application of Adipose Derived Stromal Vascular Fraction (SVF) in Cosmetic and Reconstructive Surgery.
In this presentation I will discuss these emerging technologies and techniques and describe our experience, as the first adipose derived stem cell treatment center in the U.S., in obtaining high yield lipoaspirate tissue sample utilizing the Body-Jet™ (HumanMed, Schwerin, Germany) WAL device as compared to traditional liposuction, syringe based liposuction, and competing technologies.
In addition I will discuss our experience utilizing automated SVF processing devices such as the Stem Source™ device by Cytori Inc. (San Diego, CA, USA.) and LipoKit (MediKhan, Seol, Korea) as compared to standardized manual processing methods for the purpose of obtaining graft specimen enhanced with SVF. Flow Cytometry, Growth Kinetics Assay, and Image Analysis data will be presented comparing SVF yield and MSC characterizations as seen when utilizing various techniques for harvesting and processing. A cost effective and clinically feasible solution for the routine storage of SVF enriched adipose tissue for future cosmetic as well as tissue engineering and regenerative applications will also be discussed in detail.
Dr Joseph Purita
12:00 - 13:00
Latest developments in PRP and Stem Cells injections for orthopedic applications.
The presentation concerns the use of PRP and Stem cell injections for treatment of musculoskeletal conditions. We wish to take the discussion to the next level by discussing the cutting edge of the cutting edge. Our clinic has made extensive use of Platelet Rich Plasma in conjunction with Bone Marrow Stem Cells (BMAC) and Adipose Stem Cells (SVF) and fat grafts.
We have now expanded our practice to use stem cells which until recently were thought to exist in therapy only. All of these components are harvested from the patient, minimally manipulated, and utilized the same day essentially keeping within FDA guidelines.
Vasilis Paspaliaris M.D.
CEO, Adistem Pty Ltd
13:00 - 14:00
Therapeutic potential of autologous adipose derived stem cells in chronic disease
Adipose derived stem cells are readily available from autologous adipose tissue, and have demonstrated an ability to provide significant potential for repair of damage in multiple animal models. These include models of myocardial infarction, heart failure, hind limb ischemia, neurodegenerative and inflammatory conditions.
Early clinical studies have now extended testing of the affects of ASC on patients. Clinical applications of ASCs have begun to show early safety results and promising efficacy potential in patients suffering from a range of diseases. These effects are based on the secretion of trophic and survival factors from these cells, and by their participation in the growth and remodeling of connective tissue and blood vessels.
This presentation will highlight some of the clinical trials and case study series in which the author was involved. Dr. Paspaliaris will describe the potential and mechanism of action of ASCs, particularly on diseases such as COPD, osteoarthritis, type 11 diabetes and cardiovascular disease. The results of these studies suggest that ASC could be a valuable therapeutic option in new tissue growth and tissue repair in various clinical settings.